Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
基本信息
- 批准号:8082274
- 负责人:
- 金额:$ 41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-15 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdultAdverse effectsAnimal ModelAntiviral AgentsArtemisininsBiological AssayCancer cell lineCellsClinicalComplicationCytomegalovirusCytomegalovirus InfectionsCytomegalovirus RetinitisCytomegalovirus VaccinesDNA Polymerase InhibitorDNA-Directed DNA PolymeraseDataDevelopmentDrug CombinationsEndothelial CellsEnvironmentFamilyFibroblastsFutureGanciclovirGenesGenetic TranscriptionGoalsHIVHerpesviridaeHumanImmunocompetentImmunocompromised HostImmunosuppressionIn VitroIndividualInfectionInvestigationLabelLaboratoriesLeadLigandsLuciferasesMalariaMental RetardationMinocyclineModelingMorbidity - disease rateNewborn InfantParentsPathway interactionsPatientsPharmaceutical PreparationsProtein MicrochipsProteinsProteomicsRat CytomegalovirusRecombinantsReportingResearchResistanceSafetySeriesSeroprevalencesSignal PathwayStagingTestingTherapeutic EffectTherapeutic UsesTimeTranscriptTranslationsTransplant RecipientsUnited StatesUniversitiesViralViral ProteinsVirusVirus DiseasesVirus Replicationartemisinineartesunateburden of illnesscellular targetingcohortcongenital cytomegaloviruscostcytotoxiccytotoxicitydeafnessdimereffective therapyexperiencelytic replicationmonomermortalitynovelnovel therapeuticspathogenprophylacticprotein expressionresearch studyresistant straintooltranscription factorviral DNAviral resistance
项目摘要
DESCRIPTION (provided by applicant): Cytomegalovirus (CMV) infection is common in humans, with seroprevalence rates reaching as high as 90% by adulthood. Although infection is usually asymptomatic in the normal host, CMV causes serious morbidity and mortality in immunocompromised cohorts, including transplant recipients and patients infected with HIV. CMV retinitis is a serious complication in patients with AIDS and profound immunosuppression. In addition, congenital CMV is the leading infectious cause of mental retardation and deafness in the United States. Current CMV therapies are effective in suppressing virus replication, but result in serious side effects, and the emergence of resistant viruses. Development of new compounds could significantly reduce morbidity and mortality from this pathogen. The overall goal of this application is to investigate the anti-CMV activities of artemisinins. Several artemisinin derivatives are widely used in malaria therapy. These compounds are orally available and have a good safety profile. The proposed investigation can be accomplished by our development of anti-viral assays and the availability of newly-synthesized artemisinin derivatives at Johns Hopkins University. We reported recently that dimeric artemisinins are dramatically more effective than the monomeric forms in inhibiting CMV replication in human fibroblasts. We have also shown that inhibition of CMV replication occurs at a very early stage of virus replication. The anti-CMV mechanism of artemisinins may be different than CMV inhibition by currently available compounds. We propose to identify the most potent anti-CMV artemisinin derivative, to evaluate whether combination with approved anti-CMV drugs is additive, and to elucidate mechanisms by which artemisinins inhibit CMV replication. This application is feasible and novel because we have acquired the experience and tools necessary for performing all experiments. For the first time we will use high throughput proteomics to identify the intracellular targets of artemisinins. The information derived from this application will have important impact on CMV therapy. It may lead to new concepts in CMV therapeutics by using a combination of compounds with direct anti-viral target and compounds which target a cellular protein that is important for CMV replication.
PUBLIC HEALTH RELEVANCE: Infection with Human Cytomegalovirus (CMV) is endemic, and associated with severe morbidity and mortality in congenitally-infected newborns and immunocompromised hosts. Treatment options for CMV infection are limited, and it is important to develop new therapeutic strategies against CMV. The overall aim of this proposal is to determine the activities and potential mechanisms of artemisinins as anti-CMV drugs.
描述(申请人提供):巨细胞病毒(CMV)感染在人类中很常见,成年后血清阳性率高达90%。虽然在正常宿主中通常没有感染症状,但CMV在免疫功能低下的人群中会导致严重的发病率和死亡率,包括移植受者和感染艾滋病毒的患者。巨细胞病毒视网膜炎是艾滋病患者的严重并发症和严重的免疫抑制。此外,在美国,先天性巨细胞病毒是导致智力低下和耳聋的主要传染病。目前的CMV疗法在抑制病毒复制方面是有效的,但会导致严重的副作用,并出现耐药病毒。开发新的化合物可以显著降低这种病原体的发病率和死亡率。本申请的总体目标是研究青蒿素的抗CMV活性。几种青蒿素衍生物被广泛用于疟疾治疗。这些化合物是口服的,具有良好的安全性。这项拟议的研究可以通过我们开发的抗病毒试验和约翰霍普金斯大学新合成的青蒿素衍生物的可用性来完成。我们最近报道,在抑制人成纤维细胞中的CMV复制方面,二聚体青蒿素比单体形式显著更有效。我们还表明,CMV复制的抑制发生在病毒复制的非常早期阶段。青蒿素的抗CMV作用机制可能不同于现有化合物对CMV的抑制作用。我们建议确定最有效的抗CMV青蒿素衍生物,评估与已批准的抗CMV药物是否具有相加作用,并阐明青蒿素抑制CMV复制的机制。这一应用是可行的和新颖的,因为我们已经获得了执行所有实验所需的经验和工具。我们将首次使用高通量蛋白质组学来确定青蒿素的细胞内靶点。从这一应用中获得的信息将对CMV治疗产生重要影响。通过使用具有直接抗病毒靶点的化合物和针对对CMV复制至关重要的细胞蛋白的化合物的组合,它可能会在CMV治疗中产生新的概念。
公共卫生相关性:人类巨细胞病毒(CMV)感染是地方性的,并与先天性感染的新生儿和免疫受损宿主的严重发病率和死亡率有关。巨细胞病毒感染的治疗选择有限,开发针对巨细胞病毒的新治疗策略非常重要。这项建议的总体目标是确定青蒿素作为抗CMV药物的活性和潜在机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ravit Boger其他文献
Ravit Boger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ravit Boger', 18)}}的其他基金
Autophagy activation – a novel strategy for inhibition of human cytomegalovirus
自噬激活——抑制人类巨细胞病毒的新策略
- 批准号:
10442936 - 财政年份:2022
- 资助金额:
$ 41万 - 项目类别:
Autophagy activation – a novel strategy for inhibition of human cytomegalovirus
自噬激活——抑制人类巨细胞病毒的新策略
- 批准号:
10615151 - 财政年份:2022
- 资助金额:
$ 41万 - 项目类别:
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors
用于鉴定人类巨细胞病毒抑制剂的高通量筛选
- 批准号:
8870334 - 财政年份:2014
- 资助金额:
$ 41万 - 项目类别:
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors
用于鉴定人类巨细胞病毒抑制剂的高通量筛选
- 批准号:
9056570 - 财政年份:2014
- 资助金额:
$ 41万 - 项目类别:
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors
用于鉴定人类巨细胞病毒抑制剂的高通量筛选
- 批准号:
8756332 - 财政年份:2014
- 资助金额:
$ 41万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8415971 - 财政年份:2011
- 资助金额:
$ 41万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8227951 - 财政年份:2011
- 资助金额:
$ 41万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8795657 - 财政年份:2011
- 资助金额:
$ 41万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8603834 - 财政年份:2011
- 资助金额:
$ 41万 - 项目类别:
CMV-encoded TNF receptor and viral dissemination
CMV 编码的 TNF 受体和病毒传播
- 批准号:
7640222 - 财政年份:2009
- 资助金额:
$ 41万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 41万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)